While the pharma industry attempts to expand the improved GLP-1 drug market, including orals, the generics industry will grow its GLP-1 agonist foothold, making cheaper and less efficacious injectable GLP-1 drugs much more widely available, rapidly growing the number of patients comfortable with self-injection for weight loss
In contrast, GLP-1 receptor agonists are particularly effective in reducing major adverse cardiovascular events, while their effect on HF hospitalization appears more modest, with relative risk reductions of approximately 11% (HR 0.89) in pooled analyses [6, 14]
Neurally driven hiccups tend to be brief, cluster around specific triggers such as dose changes or meals, and resolve without structural symptoms
Understanding the distinction matters, because not every GLP-1 drug lost coverage across the board